Kodiak Taq HotStart Master Mix, including dNTPs, MgCl2, and buffer
# of 20-uL
# of 20-uL
Companion enzyme master mix:
Approximately 80% of cancer patients with an EGFR L858R mutation or a variably sized deletion in EGFR exon 19 (codons 746–750) can respond to treatment with the tyrosine kinase inhibitors gefitinib and erlotinib. However, the effectiveness of such targeted therapy is often counteracted by the EGFR T790M resistance mutation. We offer qPCR assays that detect each mutation, which are available with or without a 10x master mix.
The EGFR L858 assay includes a FAM-labeled iDDS probe to detect the L858R mutation, a HEX-labeled reference iDDS probe to detect WT EGFR L858, matching antiprobes, and flanking primers.
The EGFR exon 19-deletion assay employs iDDS probes targeting the WT sequence (if present) at the exon 19 deletion site, and a reference site.
The EGFR T790M assay uses an iDDS probe to detect T790M and a Universal probe to detect a reference site.
Each assay comes with matching iDDS and/or Universal antiprobes that prevent off-target detection of similar templates and block signaling in the absence of EGFR templates.
Kodiak Taq HotStart Master Mix:
GeneTAG is offering a preferred enzyme master mix that is sold to our probe kit customers. However, other qPCR Taq enzymes are suitable for our probes.
Dual-probe error-checking assays for oncogenic EGFR mutations